Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current strategies in TB immunotherapy.

Eleanor Roy1, Douglas B Lowrie, Stephen R Jolles

  • 1Department of Medical Biochemistry and Immunology, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN UK. roye1@cardiff.ac.uk

Current Molecular Medicine
|June 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypoxia/lactate orchestrates the reprogramming metabolism of lung adenocarcinoma by modulating the SIRT2-mediated acetylation.

Journal of translational medicine·2026
Same author

Long-term complete radiological response to immunotherapy in a patient with metastatic NSCLC and active rheumatoid arthritis.

Oxford medical case reports·2026
Same author

Mitral Annular Calcification and Coronary Artery Disease: Associations and Prognostic Implications: An Up-to-Date Review.

Cardiology in review·2026
Same author

Rapid detection of drug resistance in <i>Mycobacterium tuberculosis</i> clinical isolates for first-line antitubercular drugs by using a novel reporter mycobacteriophage.

Frontiers in cellular and infection microbiology·2025
Same author

The blood biomarker combination IL-8/IL-33 and IL-18/IL-33 distinguish between active tuberculosis and latent infection.

Infection·2025
Same author

Multi-omics analysis reveals that linoleic acid metabolism is associated with variations of trained immunity induced by distinct BCG strains.

Science advances·2024

Developing novel immunotherapies could offer a solution to current tuberculosis (TB) treatment challenges. Stimulating protective immunity may lead to shorter, more effective TB regimens, avoiding drug resistance.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Pharmacology

Background:

  • Current pulmonary tuberculosis (TB) chemotherapy requires long treatment durations with multiple drugs.
  • This leads to poor patient adherence, treatment failure, and the emergence of drug-resistant Mycobacterium tuberculosis strains.
  • Shorter, more effective TB treatment regimens are urgently needed.

Purpose of the Study:

  • To review immunotherapy as an adjunct to chemotherapy for tuberculosis.
  • To emphasize evidence from human studies on modulating the host immune response to Mycobacterium tuberculosis.
  • To explore potential strategies for enhancing anti-TB immunity while avoiding detrimental immune responses.

Main Methods:

  • Review of existing literature on immunotherapy for TB.

Related Experiment Videos

  • Emphasis on human studies examining cytokine modulation, environmental mycobacteria administration, and antibody therapy.
  • Analysis of strategies to stimulate protective immunity against Mycobacterium tuberculosis.

    • Main Results:

    • Immunotherapy presents a promising avenue to overcome limitations of current TB chemotherapy.
    • Potential to avoid pathogen resistance associated with prolonged drug use.
    • Need for careful application to stimulate protective immunity, not exacerbate host-mediated pathology.

    Conclusions:

    • Immunotherapy warrants further investigation as a complementary approach to TB chemotherapy.
    • Stimulating protective host immunity is key to developing novel, shorter TB treatment regimens.
    • Future research should focus on safely enhancing immune responses to Mycobacterium tuberculosis.